In this way, DCV has demonstrated the ability to modify the tumor microenvironment and to potentiate systemic host immune responses as an active approach to treat BC patients by increasing T-cell infiltration within the tumor [58], as well as by increasing PD-L1 expression in tumoral cells and stimulating systemic T-cell activity against BC [57]. This evidence concerns the gene CD274 and breast cancer.